Real World Insights: Bispecific Antibodies in R/R MM : Episode 11
Managing CNS and Systemic Responses In R/R MM: Monitoring and Sequencing Strategies with Elranatamab and Cilta-Cel
Panelists discuss how, for a patient who has an aggressive disease, physicians will plan for monthly serum markers including serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE); if they start seeing an increase in the disease, they plan an imaging for bone marrow biopsy and consider a diagnostics lumbar puncture.
EP: 1.Meet a 76-Year-Old Patient With Late-Line R/R MM, Unsuitable For CAR T Therapy
EP: 2.Role of Step-Up Dosing
EP: 3.Dosing Frequency, and Adverse Event Management With Bispecific Therapy
EP: 4.Strategies For Management of Infections
EP: 5.Optimizing Treatment Goals and Supportive Care For Relapsed/Refractory Multiple Myeloma in Older Patients
EP: 6.Meet a 55-Year-Old Who Was Refractory to or Relapsed on BCMA CAR T Therapy
EP: 7.Patient Tolerability of Talquetamab and Use of IVIG
EP: 8.Strategizing Talquetamab Use In Relapsed/Refractory Multiple Myeloma: Balancing Efficacy, Infection Control, and Next-Line Therapy
EP: 9.Meet our 61-Year-Old Patient With Late-Line R/R on a BCMA-Targeting Bispecific
EP: 10.Dosing Strategies in Different Targets Bispecifics
Now Viewing
EP: 11.Managing CNS and Systemic Responses In R/R MM: Monitoring and Sequencing Strategies with Elranatamab and Cilta-Cel
Video content above is prompted by the following:
- What would your follow-up monitoring plan look like to assess both CNS and systemic responses to elranatamab?
- What treatment sequencing strategy would you use if disease progression occurs, particularly balancing the need for CNS efficacy and minimizing systemic toxicity?
- Given the response he has made on elranatamab, how would you counsel him on the potential benefits and risks of continuing vs sequencing to cilta-cel?
Recent Videos
Related Content
